KR20220027203A - 류코메틸티오니늄의 치료적 상호작용 - Google Patents

류코메틸티오니늄의 치료적 상호작용 Download PDF

Info

Publication number
KR20220027203A
KR20220027203A KR1020227003213A KR20227003213A KR20220027203A KR 20220027203 A KR20220027203 A KR 20220027203A KR 1020227003213 A KR1020227003213 A KR 1020227003213A KR 20227003213 A KR20227003213 A KR 20227003213A KR 20220027203 A KR20220027203 A KR 20220027203A
Authority
KR
South Korea
Prior art keywords
treatment
compound
disease
subject
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227003213A
Other languages
English (en)
Korean (ko)
Inventor
찰스 로버트 해링턴
게르노 리델
발레리아 멜리스
요헨 클라인
그라지나 니위아돔스카
마르타 스테츠코프스카
카리마 슈왑
클라우드 미셸 위스칙
Original Assignee
위스타 레보레이토리스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 위스타 레보레이토리스 리미티드 filed Critical 위스타 레보레이토리스 리미티드
Publication of KR20220027203A publication Critical patent/KR20220027203A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Steroid Compounds (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
KR1020227003213A 2019-07-01 2020-06-30 류코메틸티오니늄의 치료적 상호작용 Ceased KR20220027203A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1909493.7 2019-07-01
GBGB1909493.7A GB201909493D0 (en) 2019-07-01 2019-07-01 Therapeutic interactions
PCT/EP2020/068422 WO2021001380A1 (en) 2019-07-01 2020-06-30 Therapeutic interactions of leucomethylthioninium

Publications (1)

Publication Number Publication Date
KR20220027203A true KR20220027203A (ko) 2022-03-07

Family

ID=67540109

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227003213A Ceased KR20220027203A (ko) 2019-07-01 2020-06-30 류코메틸티오니늄의 치료적 상호작용

Country Status (12)

Country Link
US (1) US20230031369A1 (enExample)
EP (1) EP3989954A1 (enExample)
JP (1) JP7638915B2 (enExample)
KR (1) KR20220027203A (enExample)
CN (1) CN114126622A (enExample)
AU (1) AU2020298758B2 (enExample)
BR (1) BR112021025256A2 (enExample)
CA (1) CA3143790A1 (enExample)
GB (1) GB201909493D0 (enExample)
IL (1) IL289338B2 (enExample)
MX (1) MX2021015292A (enExample)
WO (1) WO2021001380A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3487505T3 (pl) 2016-07-25 2023-10-09 Wista Laboratories Ltd. Podawanie i dawkowanie diaminofenotiazyn
BR112021000802A2 (pt) 2018-07-26 2021-04-13 Wista Laboratories Ltd. Dosagem otimizada de diaminofenotiazinas em populações
GB202500018D0 (en) * 2025-01-02 2025-02-19 Wista Lab Ltd Long term dosing of neurodegenerative disorders utilising methylthioninium (mt) containing compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0100119D0 (en) 2001-01-03 2001-02-14 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
CN104119294B (zh) 2006-03-29 2018-10-30 维斯塔实验室有限公司 3,7-二氨基-10h-吩噻嗪化合物的制备方法
AU2008265045B2 (en) 2007-06-19 2014-02-27 Taurx Therapeutics Management Ltd. Phenothiazine compounds for treating Mild Cognitive Impairment
PT2954932T (pt) 2007-10-03 2018-12-12 Wista Lab Ltd Utilização terapêutica de diaminofenotiazinas
CN101911081A (zh) 2007-11-05 2010-12-08 维斯塔实验室有限公司 用于临床试验的体系
KR101888713B1 (ko) 2011-02-11 2018-08-14 위스타 레보레이토리스 리미티드 페노티아진 디아미늄 염 및 이의 용도
PL3487505T3 (pl) 2016-07-25 2023-10-09 Wista Laboratories Ltd. Podawanie i dawkowanie diaminofenotiazyn
GB201614834D0 (en) * 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
BR112021000802A2 (pt) * 2018-07-26 2021-04-13 Wista Laboratories Ltd. Dosagem otimizada de diaminofenotiazinas em populações

Also Published As

Publication number Publication date
WO2021001380A1 (en) 2021-01-07
US20230031369A1 (en) 2023-02-02
GB201909493D0 (en) 2019-08-14
IL289338B2 (en) 2026-07-01
AU2020298758A1 (en) 2022-02-24
CA3143790A1 (en) 2021-01-07
IL289338B1 (en) 2026-03-01
EP3989954A1 (en) 2022-05-04
JP7638915B2 (ja) 2025-03-04
IL289338A (en) 2022-02-01
JP2022538642A (ja) 2022-09-05
BR112021025256A2 (pt) 2022-01-25
MX2021015292A (es) 2022-01-18
AU2020298758B2 (en) 2026-07-30
CN114126622A (zh) 2022-03-01

Similar Documents

Publication Publication Date Title
JP7686581B2 (ja) 認知機能の向上薬としてのメチルチオニニウム
JP6250394B2 (ja) 軽度の認知障害（ｍｃｉ）および関連障害の処置方法
US9211294B2 (en) Phenothiazine compounds for treating mild cognitive impairment
JP5730466B2 (ja) 鉄の細胞内不良処理からもたらされるフリードライヒ運動失調症の治療及び／又は予防のための方法およびデフェリプロンの使用
US20200113882A1 (en) Use of 4-Aminopyridine to Improve Neuro-Cognitive and/or Neuro-Psychiatric Impairment in Patients with Demyelinating and Other Nervous System Conditions
JP2019526571A (ja) 認知症の処置
JP7638915B2 (ja) ロイコメチルチオニニウムの治療上の相互作用
AU2020300792B2 (en) Methylthioninium for use in the treatment of synaptopathies
JP2020500165A (ja) アルツハイマー病を治療するための抗ａベータプロトフィブリル抗体及びベータ−セクレターゼｂａｃｅ１阻害剤を含む組成物
RU2834773C2 (ru) Терапевтические взаимодействия лейкометилтиониния
RU2824584C2 (ru) Метилтиониний в качестве усилителя когнитивной функции
RU2835868C2 (ru) Метилтиониний, предназначенный для лечения синаптопатий

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000